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ABSTRACT 19 
The long-term use of antibiotics has led to the emergence of multi-drug-resistant bacteria. A 20 
promising strategy to combat bacterial infections aims at hampering their adaptability to the host 21 
environment without affecting growth. In this context, the intercellular communication system 22 
quorum sensing (QS), which controls virulence factor production and biofilm formation in 23 
diverse human pathogens, is considered an ideal target. 24 
Here we describe the identification of new inhibitors of the pqs QS system of the human 25 
pathogen Pseudomonas aeruginosa, by screening a library of 1,600 FDA-approved drugs. 26 
Phenotypic characterization of ad hoc engineered strains and in silico molecular docking 27 
demonstrated that the antifungal drugs clotrimazole and miconazole, and an antibacterial 28 
compound active against Gram-positive pathogens, clofoctol, inhibit the pqs system, probably by 29 
targeting the transcriptional regulator PqsR. The most active inhibitor, clofoctol, specifically 30 
inhibited the expression of pqs-controlled virulence traits in P. aeruginosa, such as pyocyanin 31 
production, swarming motility, biofilm formation, and expression of genes involved in 32 
siderophore production. Moreover, clofoctol protected Galleria mellonella larvae from P. 33 
aeruginosa infection and inhibited the pqs QS system in P. aeruginosa isolates from cystic 34 
fibrosis patients. Notably, clofoctol is already approved for clinical treatment of pulmonary 35 
infections caused by Gram-positive bacterial pathogens, hence this drug has considerable clinical 36 
potential as an antivirulence agent for the treatment of P. aeruginosa lung infections. 37 
 38 
INTRODUCTION 39 
The discovery and development of new drugs for use in humans is a challenging task that 40 
usually requires decade-long laboratory experimentation followed by extensive clinical trials. 41 
This process is time consuming and necessitates substantial economic investments with a high-42 
risk of failure mostly due to the poor pharmacological and pharmaceutical properties of newly 43 
identified bioactive molecules. This is particularly discouraging for antibiotic discovery as the 44 
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investment required cannot be adequately recovered because of the rapid rate at which resistance 45 
emerges (1). As a consequence, while spread of multi-resistant pathogens is accelerating at an 46 
unprecedented rate, the antibiotic discovery pipeline is running dry, with 15 big pharmaceutical 47 
companies out of 18 abandoning antibacterial discovery programmes in the last decade (2,3). 48 
The search for off-target activities in drugs already approved for human use is a promising 49 
strategy that could reduce the time and costs generally associated with conventional drug 50 
discovery processes, with a high probability of yielding bioavailable and safe compounds which 51 
can more easily and swiftly move into clinical trials (4,5). 52 
A number of studies have shown the promise of drug repurposing strategies for the 53 
identification of new antibacterial drugs (6,7). Examples are gallium nitrate and 5-fluorouracil, 54 
conventionally used for the treatment of hypercalcemia and cancer, respectively, which display 55 
growth-inhibitory activities against certain Gram-negative and Gram-positive pathogens (8,9). 56 
An alternative approach to the development of new antimicrobials is the inhibition of bacterial 57 
virulence, rather than growth (10). Recently, antivirulence activities have been identified in drugs 58 
already approved for use in humans (11). As an example, the antifungal compound 5-59 
fluorocytosine inhibits virulence factor production in the Gram-negative human pathogen 60 
Pseudomonas aeruginosa both in vitro and in a mouse model of lung infection (12). Since 61 
antivirulence drugs attenuate rather than kill pathogens they should in principle combat bacterial 62 
infections without exerting the strong selective pressure for resistance imposed by bactericidal 63 
antibiotics (10). Emergence of resistance is less likely to occur for drugs targeting bacterial 64 
social behaviours, such as the production of secreted virulence factors. Indeed, resistant mutants 65 
expressing extracellular factors that are shared by the members of the entire bacterial population 66 
are unlikely to experience a fitness advantage relative to susceptible clones (13). In this context, 67 
quorum sensing (QS) is considered to be a promising target for the identification and 68 
development of antivirulence drugs, since this intercellular communication system positively 69 
controls the expression of virulence factors in a number of different human pathogens including 70 
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P. aeruginosa (14,15). 71 
P. aeruginosa is one of the most problematic human pathogens in industrialized countries, 72 
since it causes a variety of severe infections, especially among hospitalized and 73 
immunocompromised patients (16,17). These infections are difficult to treat due to the intrinsic 74 
and acquired antibiotic resistance of P. aeruginosa (18) that is further compounded by its ability 75 
to form antibiotic tolerant biofilms (19). P. aeruginosa is the predominant cause of morbidity 76 
and mortality in  individuals with cystic fibrosis (CF), as it forms biofilms so establishing 77 
chronic lung infections impossible to eradicate with antibiotic treatment (20). The necessity for 78 
new therapeutic options for the treatment of P. aeruginosa infections was highlighted in a recent 79 
World Health Organization report, in which this pathogen is top ranked among pathogens for 80 
which new antibiotics are urgently needed (Priority 1 - Critical; 81 
www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/). 82 
As a consequence of its importance as a human pathogen, P. aeruginosa has been adopted as 83 
a model organism for QS inhibition studies. This bacterium is endowed with a complex QS 84 
network consisting of four interconnected systems (i.e. las, rhl, pqs and iqs), which collectively 85 
control social behaviours and the expression of virulence determinants, such as secreted 86 
virulence factors, swarming motility and biofilm formation (21,22). Over the last decade, 87 
numerous compounds interfering with the P. aeruginosa QS circuitry have been identified, and 88 
their effectiveness as antivirulence drugs both in vitro and in vivo has boosted the research in the 89 
field (23). Unfortunately, most of the drugs identified so far are cytotoxic or display 90 
unfavourable pharmacological properties, thus limiting their transfer to clinical practice (15). 91 
To combine the advantages of drug-repurposing with the antivirulence approach, we 92 
previously showed that the anthelmintic drug niclosamide has potent antivirulence activity 93 
against P. aeruginosa (24). Niclosamide targets the las QS system, thereby decreasing the 94 
expression of las-controlled virulence factors and protecting Galleria mellonella larvae from P. 95 
aeruginosa infection (24). 96 
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In the present study we searched for inhibitors of the pqs QS system of P. aeruginosa among 97 
drugs already approved for human use. 98 
The pqs QS system of P. aeruginosa is based on 2-alkyl-4-quinolones (AQs) as signal 99 
molecules, namely 2-heptyl-3-hydroxy-4-quinolone (PQS), and its immediate precursor 2-100 
heptyl-4-hydroxyquinoline (HHQ). Both HHQ and PQS can bind to and activate the 101 
transcriptional regulator PqsR (also known as MvfR). The PqsR/HHQ and PqsR/PQS complexes 102 
bind the PpqsA promoter region and trigger the transcription of the pqsABCDEphnAB operon, 103 
coding for the enzymes required for the synthesis of HHQ. HHQ is in turn oxidized to PQS by 104 
the monooxygenase PqsH. Therefore, in common with other QS systems, HHQ and PQS act as 105 
autoinducers by generating an autoinductive feedback loop that accelerates their synthesis (25-106 
28). 107 
While HHQ only activates the expression of the pqsABCDEphnAB operon, PQS has 108 
additional functionalities; it is an iron chelator, participates in the formation of outer membrane 109 
vesicles and controls the expression of virulence genes via a PqsR-independent pathway (28-31). 110 
The mechanism of action of the protein coded by the fifth gene of the pqsABCDEphnAB 111 
operon, PqsE, is still poorly understood. PqsE is a pathway-specific thioesterase, which 112 
contributes to the synthesis of HHQ, although loss of its function can be compensated for by 113 
other thioesterases in a pqsE mutant (27). Notably, PqsE positively controls the expression of 114 
multiple virulence factors also in a P. aeruginosa genetic background in which it cannot 115 
participate to AQs biosynthesis, indicating that this protein has additional functions (29,32,33). 116 
Overall, P. aeruginosa mutants defective in AQ synthesis/reception or in PqsE are severely 117 
attenuated in different plant and animal experimental models of infection (33-38). Moreover, 118 
AQs are detectable in sputum, blood and urine of individuals with CF and their presence 119 
correlates with clinical status (39). 120 
In this study, a convenient screening system has been developed and used to select for FDA-121 
approved drugs targeting the pqs QS system at multiple levels. This screening campaign led to 122 
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the identification of the antifungal drugs clotrimazole and miconazole, and of clofoctol, an 123 
antimicrobial compound commonly used to treat lung infections caused by Gram-positive 124 
bacteria, as inhibitors of pqs signaling, probably targeting the PqsR receptor protein. Phenotypic 125 
analyses performed in the laboratory strain PAO1 and in P. aeruginosa isolates from CF patients 126 
support the antivirulence potential of clofoctol, the most active inhibitor. 127 
 128 
RESULTS 129 
Development of a coculture-based system for monitoring pqs signaling activity 130 
A reporter system for monitoring the activity of the pqs QS system has been developed. This 131 
is based on the coculture between wild type P. aeruginosa PAO1 (herein referred to as PAO1) 132 
and the AQ biosensor strain P. aeruginosa ∆pqsA PpqsA::luxCDABE (herein referred to as AQ-133 
Rep; Table S1). AQ-Rep cannot synthesize AQs due to deletion of the pqsA biosynthetic gene, 134 
and emits light only in response to exogenously provided AQs due to PqsR-dependent activation 135 
of the PpqsA::luxCDABE transcriptional fusion integrated in a neutral chromosomal site (31). 136 
Therefore, in the PAO1/AQ-Rep coculture system the AQ signal molecules produced by PAO1 137 
induce bioluminescence, and hence pqs inhibitors interfering with each step of the pqs signaling 138 
circuit, including AQ biosynthesis or response, should reduce bioluminescence (Fig. 1A). 139 
Preliminary experiments directed towards setting-up the screening system revealed that 140 
maximal response of AQ-Rep to exogenous PQS was obtained after 5 h incubation in microtiter 141 
plates (Fig. S1A), when this biosensor strain was inoculated at an optical density at 600 nm 142 
wavelength (OD600) of 0.1 (Fig. S1B). Cocultivation of AQ-Rep and PAO1 at different ratios and 143 
in different culture conditions showed that the highest bioluminescence signal was registered 144 
when AQ-Rep and PAO1 were inoculated in a ~ 3:1 ratio (OD600 of AQ-Rep and PAO1 of 0.1 145 
and 0.03, respectively) (Fig. S1C), and the resulting coculture was incubated at 37°C with 146 
shaking (Fig. S1D). Therefore, the screening campaign has been set-up under the above 147 
conditions to maximize the biosensor responsiveness to AQs and possibly to drugs interfering 148 
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with AQ signaling. 149 
The functionality of the PAO1/AQ-Rep coculture system for the identification of anti-pqs 150 
drugs was assessed using the commercially available compounds methyl anthranilate and 151 
farnesol. Methyl anthranilate inhibits AQs biosynthesis by competing with the HHQ precursor 152 
anthranilate for binding to PqsA (40), while farnesol decreases the expression of HHQ 153 
biosynthetic genes via an unknown mechanism (41). As expected, both methyl anthranilate and 154 
farnesol reduced bioluminescence from the PAO1/AQ-Rep coculture in a dose-dependent 155 
manner, with an IC50 of ca. 1 mM (Fig. 1B), in accordance with literature data (40-41). 156 
 157 
Identification of new anti-pqs drugs 158 
The PAO1/AQ-Rep coculture system was used to screen a library of 1,600 FDA-approved 159 
compounds with known biological activities selected for their high chemical and 160 
pharmacological diversity and safety in humans (PHARMAKON). In the primary screening, 161 
each drug was tested at two different concentrations, 20 µM and 200 µM, for the ability to 162 
reduce bioluminescence in the PAO1/AQ-Rep coculture. Since compounds from the library are 163 
dissolved in dimethyl sulfoxide (DMSO), untreated samples containing the same amount of 164 
DMSO as the treated samples were used as controls. Cell density and bioluminescence of the 165 
untreated samples were considered as 100%, and the criteria for selection of anti-pqs drugs were: 166 
i) inhibition of bioluminescence ≥ 20% at 20 µM; ii) inhibition of bioluminescence ≥ 60% at 200 167 
µM; iii) reduction of cell density ≤ 10% at both 20 µM and 200 µM. This primary screening led 168 
to the selection of seventeen hits meeting these criteria (Fig. S2A) and possibly endowed with 169 
pqs inhibitory activity. 170 
However, reduced bioluminescence in the samples treated with the selected drugs could be 171 
due to their effects on the enzymes involved in light generation or on ATP levels (42,43). Since 172 
inhibition of PpqsA promoter activity in P. aeruginosa should decrease the production of the AQs 173 
HHQ and PQS, a secondary screening to test the ability of the seventeen hits to reduce AQ 174 
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production in PAO1 was performed. In this case, AQ levels were measured by means of the AQ-175 
Rep biosensor strain in the spent medium from PAO1 cultures grown for 16 h in Luria-Bertani 176 
Broth (LB) supplemented with the selected hits at 20 µM or 200 µM concentrations, or with 177 
corresponding amounts of DMSO. This analysis revealed that only three drugs specifically 178 
reduced the production of AQs in PAO1: clotrimazole, clofoctol and miconazole (I-3, I-9 and I-179 
14 in Fig. S2B, respectively). Two of the drugs identified, clotrimazole and miconazole, are 180 
antifungal compounds (44-47), while clofoctol is an antibacterial drug with efficacy in Gram-181 
positive human lung infections (48-50) (Table 1). 182 
To confirm the results of the primary and secondary screening, clotrimazole, clofoctol and 183 
miconazole were purchased from an alternative supplier (Sigma-Aldrich). These drugs did not 184 
inhibit PAO1 growth in Muller-Hinton Broth or LB even at the highest concentration achievable 185 
in solution (i.e. MIC clotrimazole > 1.6 mM; MICs for miconazole and clofoctol > 6.4 mM). 186 
Moreover, these drugs did not alter the growth profile of wild type PAO1 and of the AQ-Rep 187 
biosensor strain up to the maximum concentration used in the primary and secondary screenings 188 
(i.e. 200 µM; Fig. S3). 189 
The pqs inhibitory activity of the drug hits was retested in the PAO1/AQ-Rep coculture assay. 190 
Dose-response inhibition of PpqsA promoter activity was observed for the three drugs (Fig. 2A). 191 
These data generated IC50 values of 39 µM, 20 µM and 27 µM for clotrimazole, clofoctol and 192 
miconazole, respectively (Table 1). The three hits had no effect on bioluminescence in a P. 193 
aeruginosa strain in which the expression of the luxCDABE operon for light emission is 194 
independent on the activity of the pqs signaling system (Fig. S4), ruling out the possibility that 195 
the inhibitory activity on the PAO1/AQ-Rep coculture was due to no-specific inhibition of 196 
bioluminescence. Moreover, the three drugs confirmed their ability to reduce AQ production in 197 
PAO1 in a dose-dependent manner (Fig. 2B), in accordance with the repressive effect exerted on 198 
the PpqsA promoter. 199 
The QS cascade in P. aeruginosa is a complex network of interwoven and hierarchical QS 200 
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circuits (21,22), and hence the effect of some compounds on the pqs QS system may be due to 201 
altered activity of the las and/or rhl QS systems. In particular, the las QS system is required for 202 
full activation of the pqs QS systems (36,51-53), while RhlR has a negative impact on the pqs 203 
system by repressing PQS signal production through interference with the expression of pqsR 204 
and pqsABCDE (36,54-56). Hence, reduced activity of the pqs QS system could be due to a 205 
negative or a positive effect of the hits on the las or the rhl QS systems, respectively. Therefore 206 
possible effect of the three hits on these QS systems was investigated by using las- and rhl-207 
specific biosensor strains. Clotrimazole, clofoctol and miconazole did not decrease light 208 
emission in a reporter system in which PAO1 wild type and the las-specific biosensor strain 209 
PA14 ∆lasI PrsaL::luxCDABE were cocultured (Fig. S5A; 57). Conversely, the three compounds 210 
slightly decreased (from 15% to 30% at 200 µM) light emission from a coculture system based 211 
on PAO1 wild type and on the rhl-specific biosensor strain PAO1 ∆rhlI PrhlA::luxCDABE (Fig. 212 
S5B; 24). These data demonstrate that clotrimazole, clofoctol and miconazole do not affect the 213 
las QS system, while these drugs have a slight negative effect on the rhl QS system. Considering 214 
that i) the repressive effect exerted by the hits on the pqs QS system (Fig. 2A) occurs at lower 215 
concentration and is more pronounced than the repressive effect exerted by the same molecules 216 
on the rhl QS system (Fig. S5B), and that ii) the pqs system exerts a positive effect on the rhl 217 
system (54,58), these data support a primary activity of the hits on the pqs QS system, that 218 
consequently reduces rhl activity. 219 
Overall, these data confirm that clotrimazole, clofoctol and miconazole exert an anti-pqs 220 
activity without altering P. aeruginosa growth. 221 
 222 
Characterization of the mechanism of action of the newly identified pqs inhibitors 223 
The inhibition of PpqsA activity in the PAO1/AQ-Rep coculture system (Fig. 2A) may be due 224 
to inactivation of AQ biosynthesis in the PAO1 strain or of AQ reception in both PAO1 and AQ-225 
Rep strains (Fig. 1A). Similarly, the reduced AQ levels in PAO1 (Fig. 2B) could also be due to 226 
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inhibition of either AQ biosynthesis or response, due to the PqsR-dependent regulatory loop 227 
governing transcription of the HHQ biosynthetic enzymes (36,55). 228 
To discriminate between these two possibilities, the effect of the three drugs on AQ 229 
production was tested in a PAO1 ∆pqsA∆pqsH double mutant strain (∆pqsAH; Table S1) 230 
carrying the pFD-pqsABCD plasmid for constitutive expression of the HHQ biosynthetic 231 
enzymes. In this genetic background, in which AQ production does not depend on the ability of 232 
AQs to activate PpqsA via PqsR, the inhibitors did not reduce AQ levels, demonstrating that they 233 
do not affect the functionality of the enzymes required for HHQ biosynthesis (Fig. 3A). 234 
Moreover, the inhibitors were effective in reducing bioluminescence emission by the AQ-Rep 235 
biosensor strain grown in the presence of synthetic PQS (Fig. 3B), suggesting that the inhibitors 236 
target the PqsR-dependent AQ response rather than biosynthesis. 237 
To validate this hypothesis, we investigated the effect of the hits on the levels of pqsR mRNA 238 
and PqsR protein. As shown in Fig. 4A, Real Time RT-PCR analysis revealed that the hits do not 239 
affect pqsR mRNA levels. Moreover, Western immunoblotting showed that the inhibitors do not 240 
reduce PqsR protein levels in a PAO1 ∆pqsA∆pqsH∆pqsR triple mutant strain (∆pqsAHR; Table 241 
S1) carrying the pPqsR-6H plasmid for IPTG-inducible expression of a 6xHis-tagged variant of 242 
PqsR (Fig. 4B; 59). Actually, clotrimazole increased PqsR levels, indicating that this drug has a 243 
positive effect on the translation of the pqsR mRNA or on PqsR stability. However, clotrimazole 244 
decreased PpqsA activity (Fig. 2A) and AQs production (Fig. 2B), and reduced the mRNA level 245 
of pqs-controlled genes, as demonstrated by Real Time RT-PCR analysis performed on total 246 
mRNA extracted from PAO1 wild type grown in the absence or in the presence of 100 µM 247 
clotrimazole (Fig. S6). Overall, despite increasing PqsR level, clotrimazole seems to hamper the 248 
ability of this transcriptional regulator to activate gene expression. 249 
To support PqsR as a target of the hits, we investigated their ability to reduce light emission 250 
from the PpqsA::luxCDABE transcriptional fusion in a PAO1 triple mutant strain unable to 251 
synthesize AQs and to produce PqsR (i.e. PAO1 ∆pqsAHR), carrying the pPqsR-6H plasmid for 252 
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IPTG-inducible expression of PqsR. Cultures of this strain were grown in LB supplemented with 253 
10 µM PQS, to induce PpqsA activity, with a fixed concentration of the hits (100 µM), and with 254 
increasing concentrations of IPTG. The rationale of this experiment is that increased expression 255 
of PqsR, due to increased concentration of IPTG, should decrease the repressive effect exerted 256 
by the hits on PpqsA, if PqsR is the target of the hits. As shown in Fig. 4C, the inhibitory effect 257 
exerted by the hits on PpqsA activity decreased in parallel to increasing IPTG concentration in 258 
the growth medium, thus supporting PqsR as their molecular target. Overall, these data indicate 259 
that each of the hits acts downstream of pqsR expression, likely hampering PqsR functionality. 260 
To support the hypothesis that the inhibitors directly interact with PqsR, molecular docking 261 
simulations were performed based on the crystal structure of the PqsR co-inducer binding 262 
domain (CBD) in the apo form (PDB ID: 4JVC) (59). To increase the reliability of the 263 
simulations, the docking search space encompassed the entire CBD of PqsR, i.e. a “blind” 264 
docking procedure was carried out. Amino acid residues previously reported to be involved in 265 
the binding of the natural ligand 2-nonyl-4-hydroxy-quinoline (NHQ) to the PqsR CBD (59) 266 
were considered flexible (see Materials and Methods for details). This analyses indicated that the 267 
three hits bind PqsR with high affinity at the same site as the natural ligand NHQ (Fig. 5) with 268 
predicted ∆G values for binding of clotrimazole, clofoctol and miconazole being -8.4, -9.8 and -269 
8.5 kcal/mol, respectively. Interestingly, these values are lower than the predicted ∆G value for 270 
binding of NHQ (-7.9 kcal/mol; Table 1). Similar results were obtained when using the PqsR 271 
CBD structure bound to NHQ (PDB ID: 4JVD) (59), from which the ligand was removed. In the 272 
latter case, ∆G values for binding of clotrimazole, clofoctol, miconazole and NHQ were -9.4, -273 
9.9, -8.1 and -8.1 kcal/mol, respectively. Finally, maintaining all the CBD residues in a fixed 274 
position yielded very similar results (data not shown). Interestingly, in each case the predicted 275 
affinity of the hits for PqsR parallels their efficacy as pqs inhibitors (Table 1). 276 
Overall, these data suggest that the newly identified inhibitors could be endowed with a 277 
similar mechanism of action, that is to hamper PqsR functionality by competing with AQ 278 
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agonists for PqsR binding. Also the evidence that clotrimazole increases PqsR level (Fig. 4B) 279 
while hampering its ability to drive AQ production (Fig. 2B) and to activate pqs-controlled genes 280 
(Figs. 2A and S6) supports direct interaction of this hit to PqsR. 281 
Notably, both activity assays and in silico predictions indicate that clofoctol has greater 282 
inhibitory activity relative to miconazole and clotrimazole (Table 1). To support competitive 283 
binding of PQS and clofoctol to PqsR, the ability of this drug to repress PpqsA activity was 284 
evaluated in the AQ-Rep biosensor grown in the presence of a range of concentrations of the 285 
native PqsR agonist PQS. This competition assay revealed the reduced ability of clofoctol to 286 
inhibit PpqsA activity in the presence of increasing concentrations of PQS (Fig. S7), in 287 
accordance with the activity of clofoctol as a competitive antagonist of the PQS receptor protein 288 
PqsR. 289 
 290 
Clofoctol inhibits the expression of pqs-controlled virulence phenotypes 291 
By hampering the ability of PqsR to activate the transcription of the pqsABCDE operon, 292 
clofoctol is expected to reduce the expression of virulence traits controlled by both PQS and 293 
PqsE in P. aeruginosa. First of all, since the assays previously performed to assess the effect of 294 
clofoctol on AQ production did not discriminate between HHQ and PQS, these QS signal 295 
molecules were quantified by liquid chromatography - tandem mass spectrometry (LC-MS/MS) 296 
analysis of spent media from PAO1 cultures treated with a range of concentrations of clofoctol. 297 
As shown in Fig. 6A, this analysis confirmed that clofoctol inhibits AQ production in P. 298 
aeruginosa, with both HHQ and PQS concentrations being significantly reduced by the drug. 299 
With respect to the effect of clofoctol on PQS- and PqsE-controlled virulence determinants, 300 
phenotypic analyses revealed that 100 µM clofoctol leads to > 80% reduction in pyocyanin (Fig. 301 
6B), and considerably reduced swarming motility (Fig. 6C). Moreover, 100 µM clofoctol 302 
significantly reduced biofilm formation in a PAO1 strain constitutively expressing GFP via the 303 
pMRP9-1 plasmid (60) (Fig. 6D). Notably, the effect of clofoctol on the tested phenotypes in 304 
 13 
PAO1 mimicked deletion of the pqsR gene (∆pqsR; Fig. 6B-D), in accordance with the 305 
hypothesis that PqsR is the clofoctol target. 306 
Subsequently, Real Time RT-PCR analyses were performed to examine the effect of clofoctol 307 
on the expression of pqs-controlled virulence genes (28). The PQS-dependent pvdS and pchR 308 
genes code for the PvdS and PchR regulatory proteins required for the synthesis of the 309 
siderophores pyoverdine and pyochelin, respectively (28,61); the PqsE-dependent lecA gene 310 
codes for the LecA lectin involved in the formation of antibiotic-resistant biofilms (28,62). As a 311 
control, the mRNA level of pqsA was also measured. Real Time RT-PCR analyses showed that 312 
clofoctol significantly decreased the mRNA level of each of the genes tested, in agreement with 313 
the down-regulation observed in a PAO1 ∆pqsR mutant strain (Fig. 6E). The negative effect 314 
exerted by clofoctol on lecA transcription was also confirmed by promoter activity assay 315 
showing reduced activity of the PlecA::luxCDABE transcriptional fusion in PAO1 cultures 316 
treated with clofoctol (Fig. S8). 317 
Overall, these data support clofoctol as an antivirulence agent active against the P. aeruginosa 318 
pqs QS system. 319 
 320 
Clofoctol protects Galleria mellonella larvae from P. aeruginosa infection and inhibits the 321 
pqs QS system in CF clinical isolates 322 
The antivirulence activity of clofoctol was tested in G. mellonella larvae, an insect infection 323 
model which correlates well with P. aeruginosa mouse infection models (63). Firstly, G. 324 
mellonella was infected with ca. 10 cells of P. aeruginosa PAO1 or of the isogenic ∆pqsR mutant 325 
and incubated at 37°C for 120 h. As shown in Fig. 7A, mutation of pqsR significantly reduced 326 
the ability of P. aeruginosa to kill the larvae, demonstrating the suitability of this insect model to 327 
investigate the antivirulence potential of drugs targeting PqsR. 328 
Since the average weight of G. mellonella larvae was ca. 500 mg, and arbitrarily assuming 329 
uniform dispersal of injected bacteria and clofoctol in 500 µL of larval volume (64,65), 10 µL of 330 
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saline containing 5 mM clofoctol were injected to give 100 µM clofoctol in each larva. 331 
Preliminarily, we verified that the injection of 10 µL of saline containing 5 mM clofoctol did not 332 
affect the survival of uninfected larvae, and that 2 h incubation of P. aeruginosa with 5 mM 333 
clofoctol did not affect P. aeruginosa growth and viability (data not shown). Then, G. mellonella 334 
larvae were inoculated with P. aeruginosa PAO1 in the absence or in the presence of clofoctol. 335 
The treatment with clofoctol led to a survival percentage of 87%, similar to that observed with 336 
the ∆pqsR mutant (83%), while only 50% of untreated G. mellonella larvae survived PAO1 337 
infection (Fig. 7A). Overall, these data demonstrate that clofoctol attenuates P. aeruginosa PAO1 338 
lethality in G. mellonella. 339 
To verify that clofoctol is active also against clinical P. aeruginosa strains, its ability to 340 
reduce AQ production was evaluated in a collection of 20 P. aeruginosa isolates from the lungs 341 
of CF patients, grouped into four categories with respect to the stage of infection (Table S2). A 342 
preliminary analysis revealed that only 2 strains isolated from patients with more than 15 years 343 
of chronic infection (chronic late group) did not produce detectable levels of AQs (Table S2), 344 
hence these strains should be considered resistant to the antivirulence effect of clofoctol. The 345 
remaining 18 clinical isolates were grown in LB for 24 h in the absence or presence of 100 µM 346 
clofoctol, and the AQ concentration determined in the corresponding spent media by using the 347 
AQ-Rep biosensor. Residual AQ production was estimated for each treated isolate relative to the 348 
amount of AQ detected in the corresponding untreated sample, considered as 100%. Notably, 349 
clofoctol decreased AQ production in each of the clinical isolates tested, with a reduction 350 
ranging from 12.7% to 88.4% (Fig. 7B). The median reduction in AQ production in the tested 351 
isolates was 68.6%, hence comparable with the reduction in AQ levels measured in PAO1 352 
treated with 100 µM clofoctol under the same conditions (65.7%; Fig. 7B). Differences in the 353 
median reduction values among the analysed groups were not statistically significant. Moreover, 354 
differences in the median reduction of AQ production were not significant also when grouping 355 
the isolates according to their antibiotic resistance profiles (Table S2). Indeed, the median 356 
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reduction of AQ levels was 71.6% and 67.4% in 4 antibiotic susceptible and in 12 antibiotic 357 
resistant strains, respectively (Fig. S9). Also the 2 multidrug resistant (MDR) or extensively drug 358 
resistant (XDR) strains analysed in this study were susceptible to clofoctol, with a reduction of 359 
AQs levels of 56.5% and 88.4%, respectively (Fig. S9). Although performed on a limited 360 
number of clinical isolates, this analysis indicates that clofoctol is effective in blocking the pqs 361 
QS system in CF strains, irrespective of their adaptation to the host environment during long 362 
lasting chronic lung infection and of their antibiotic resistance profiles. 363 
 364 
DISCUSSION 365 
As a consequence of widespread antibiotic resistance, inhibition of virulence rather than 366 
growth has become a viable approach for combatting bacterial infections with lower selective 367 
pressure for emergence of resistance (10). In particular, in vitro evolution experiments suggest 368 
that resistant mutants will not emerge for drugs targeting public goods, such as virulence factors 369 
that are secreted and shared between individuals (66). Moreover, since antivirulence drugs target 370 
specific bacterial functions required for infection, these molecules are not expected to impact on 371 
the beneficial resident microbiota relative to that of antibiotics (11,13). 372 
In many bacterial pathogens QS positively controls the expression of multiple secreted 373 
virulence factors, hence this communication system is considered a promising target for the 374 
development of antivirulence agents (23,67). Since P. aeruginosa has four interconnected QS 375 
systems that positively control the production of virulence factors and biofilm formation, most of 376 
the research on QS inhibition has focused on this bacterium as a model system. Indeed, several 377 
molecules inhibiting the las QS system of P. aeruginosa have been identified (23,67). Recently, 378 
a number of studies have described inhibitors of the pqs QS system. The pqs system positively 379 
controls the expression of multiple virulence determinants, including secreted virulence factors 380 
and biofilm formation, and pqs mutant strains display attenuated virulence in plant and animal 381 
models of infection (32-35,38). Moreover, the pqs system is active during P. aeruginosa 382 
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infections in humans (39,68,69). 383 
Inhibitors of the pqs system were previously identified among analogs of anthranilate, the 384 
substrate of PqsA in the first step of the biosynthetic route leading to AQ production (37,40). 385 
Subsequently, compounds binding to the AQ-biosynthetic enzyme PqsD were shown to act as 386 
potent pqs inhibitors, with IC50 values in the low µM range (from 1 to 14 µM) (70,71). The 387 
possibility of interfering with the pqs system via enzymatic degradation of the AQ signals, rather 388 
than via small molecules targeting their biosynthesis, was also explored, and PQS degrading 389 
activity has been described in Arthrobacter nitroguajacolicus and Achromobacter xylosoxidans 390 
(72,73). However, the majority of anti-pqs molecules identified so far are competitive inhibitors 391 
of the transcriptional regulator PqsR. Potent PqsR antagonists with IC50 values ranging from 0.4 392 
to 38.5 µM have been found among analogs of the natural agonists HHQ and PQS (59,74-76). 393 
Whole-cell high-throughput screening and structure-activity relationship analyses led to the 394 
identification of benzamide-benzimidazole PqsR inhibitors with low IC50 values (< 1 µM) some 395 
of which also inhibited the PqsBC complex (77-79). Also 2-sulfonylpyrimidines were identified 396 
hampering both AQ reception and biosynthesis (80). Overall, a number of reports validated the 397 
antivirulence potential of anti-pqs molecules, showing their ability to reduce the expression of 398 
pqs-controlled virulence traits both in vitro and in animal models of infection. Despite the 399 
promise of anti-pqs agents for the treatment of P. aeruginosa infections, to the best of our 400 
knowledge none of these molecules has so far entered clinical trials. This is probably due to the 401 
poor pharmacological properties of the inhibitors, including possible cytotoxicity, and to the lack 402 
of ADME-TOX studies required for their evaluation in humans. In this context, searching for 403 
off-target activities in drugs already approved for use in humans represents a potential shortcut 404 
for developing new anti-pqs molecules that could move straight into clinical trials. 405 
In this study, a drug-repurposing approach led to the identification of three promising anti-pqs 406 
drugs already used in humans, by screening a library of 1,600 FDA-approved compounds (Table 407 
1; Fig. S2). Data on the acute and chronic toxicity are already available for these drugs, as well 408 
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as information on their pharmacokinetics. Clotrimazole and miconazole are antifungal drugs 409 
used in humans to treat ring worm, pityriasis versicolor, vaginal and oral candidiasis and skin 410 
yeast infections (44,45,81,82). They both alter the permeability of the fungal cell wall by binding 411 
to phospholipids and inhibiting the biosynthesis of ergosterol and other sterols required for 412 
fungal cell membrane integrity (83,84). Miconazole displays its activity by inhibiting fungal 413 
peroxidases, which results in peroxide-mediated cell death (83). Both of these drugs are mainly 414 
administered as creams or ointments, thus their current formulations could be particularly 415 
suitable for topical treatment of chronic wound infections caused by P. aeruginosa (85,86). 416 
However, this opportunistic pathogen is a main cause of lung infections especially in individuals 417 
with CF, where it establishes chronic infections that can last for decades (87). The use of 418 
clotrimazole and miconazole to treat P. aeruginosa lung infections would require their 419 
reformulation as inhalable nanosuspensions, an approach that has recently demonstrated its value 420 
for repurposing the anthelmintic drug niclosamide as an anti-QS agent against P. aeruginosa 421 
(24,88). 422 
Out of the 1,600 compounds tested in this screening campaign, the most promising anti-pqs 423 
drug was clofoctol, an antimicrobial used for the treatment of acute and chronic upper respiratory 424 
tract infections and for tracheobronchial infections caused by Gram-positive pathogens, 425 
especially staphylococci, pneumococci and streptococci (48,50). Clofoctol is also used in 426 
preventive and curative treatment of otolaryngology and stomatology (89). The mechanism of 427 
action of this drug as an antimicrobial is still poorly understood, but a detrimental effect of 428 
clofoctol on membrane and cell wall biosynthesis in Gram-positive bacteria has been reported 429 
(49,90). Clofoctol is usually administered as suppositories as it is well absorbed through the 430 
rectal mucosa and rapidly spreads through the tissues, reaching the highest concentrations in the 431 
respiratory system (91). Since clofoctol mainly acts in the airways, it is potentially valuable as a 432 
future treatment of P. aeruginosa lung infections. Notably, clofoctol is used to treat infections in 433 
infants, and this is another advantageous feature if considering that in CF, P. aeruginosa lung 434 
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infection is established in early life (92). 435 
Overall, despite their lower potency compared with other pqs inhibitors described so far, the 436 
anti-pqs drugs identified in this study have considerable potential for human use, and could be 437 
directly tested in clinical trials or serve as chemical scaffolds for future drug-optimization 438 
programmes. 439 
With respect to the mechanism of action of the three FDA-approved drugs, they all affect 440 
PqsR functionality, probably by competing with the natural ligands HHQ and PQS for the PqsR 441 
ligand-binding site (Figs. 3, 4 and S7). This hypothesis is supported by docking simulations, 442 
which predict that all three compounds bind to the PqsR co-inducer binding domain in the same 443 
binding site as the natural ligand NHQ (Fig. 5). This result was somehow unexpected, since the 444 
PAO1/AQ-Rep coculture used in the screening campaign should primarily identify molecules 445 
affecting both AQ biosynthesis and AQs reception (Fig. 1A). Indeed, this coculture-based 446 
reporter system was functional in identifying the PqsA-inhibitor methyl anthranilate (Fig. 1B). 447 
Intriguingly, the anti-QS activity of the anthelmintic drug niclosamide was discovered using a 448 
coculture-based reporter system similar to the one deployed in this work. In common with 449 
clofoctol, niclosamide inhibited the QS signal molecule response rather than biosynthesis (24). 450 
Therefore, the selection of drugs targeting QS receptors could be a bias intrinsic to the screening 451 
system used. In fact, in coculture-based screening systems, drugs interfering with QS signal 452 
molecule receptor would have a dual outcome since they would block both QS signal receptor 453 
and consequently signal biosynthesis in the wild type, as well as inhibiting the QS receptor in the 454 
reporter strain. Conversely, an inhibitor of QS signal molecule biosynthesis would only affect the 455 
functionality of the P. aeruginosa wild type strain. Hence, the PAO1/AQ-Rep coculture system 456 
may offer a more sensitive screen for PqsR inhibitors than for those that inhibit AQ biosynthesis, 457 
so that only drugs targeting PqsR will meet the selection criteria for the primary screen. 458 
Since each of the hits identified in this study are likely to target PqsR, we focused our 459 
attention on the most potent inhibitor, clofoctol (Table 1). 460 
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Different elements of the pqs QS system have recently been shown to control distinct 461 
virulence traits. In particular, the PQS signal molecule drives the expression of genes required 462 
for the biosynthesis of siderophores and of genes coding for PrpL and AprX proteases, and 463 
exotoxin S, while PqsE is required for the production of pyocyanin, LecA and LecB lectins, 464 
hydrogen cyanide, rhamnolipids and ChiC chitinase (28). With regard to pleiotropic virulence 465 
phenotypes such as swarming motility and biofilm formation, these appear to be regulated by 466 
both PQS and PqsE (33). Consistent with the activity of clofoctol as a PqsR inhibitor, the 467 
expression of both PQS-controlled virulence traits, such as the expression of genes required for 468 
siderophores biosynthesis (Fig. 6E), and of PqsE-dependent phenotypes, including pyocyanin 469 
production (Fig. 6B) and expression of the lecA gene (Figs. 6E and S8), were inhibited. 470 
Moreover, clofoctol reduced both swarming motility and biofilm formation (Figs. 6C and 6D). 471 
Notably, clofoctol exerted an antivirulence effect in vivo, since this drug attenuated P. 472 
aeruginosa infection in G. mellonella larvae (Fig. 7A). 473 
A major concern with respect to the use of anti-QS drugs for the treatment of CF pulmonary 474 
infection originates from evolutionary selection driving P. aeruginosa adaptation to the CF lung. 475 
Indeed, during chronic infections, CF isolates accumulate mutations that reduce the production 476 
of virulence factors, lead to the formation of mucoid biofilms, increase antibiotic resistance 477 
mainly as a consequence of efflux pump over-expression, and in some cases inactivated QS 478 
systems (93-96). Since P. aeruginosa QS-defective mutants should be considered resistant to 479 
anti-QS drugs, the suitability of QS-inhibition for CF therapy is under debate. However, most 480 
studies have focused on the inactivation of the las QS system in chronic CF isolates, while little 481 
attention has so far been given to the pqs QS system (97-100). The evidence that AQs have been 482 
identified in the sputum of CF patients with both intermittent and chronic P. aeruginosa 483 
infections demonstrate unequivocally that the pqs QS system is active in the CF lung 484 
(68,69,99,101). In addition, AQs can be detected in the sputum, plasma and urine of ca. 80% of 485 
CF patients suffering with P. aeruginosa chronic lung infections. Levels of the AQ molecule 486 
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NHQ increased at the start of a pulmonary exacerbation and positively correlated with 487 
quantitative measures of P. aeruginosa cells in the lung (39). This evidence is consistent with the 488 
results obtained in this study, since only 2 out of the 20 clinical isolates tested did not produce 489 
detectable levels of AQs (Table S2). Notably, clofoctol reduced functionality of the pqs QS 490 
system in all the pqs-proficient CF isolates, irrespective of their antibiotic resistance profiles 491 
(Fig. 7B and Fig. S9). 492 
Future analyses performed on a larger panel of P. aeruginosa clinical isolates from both CF 493 
and chronic wound patients and in vivo assays in murine models of infection are required to 494 
better assess the suitability of clofoctol, clotrimazole and miconazole for the treatment of P. 495 
aeruginosa chronic infections. However, the results of this work should encourage further 496 
preclinical studies to aid transfer of the newly identified pqs inhibitors from the laboratory into 497 
clinical practice. 498 
 499 
MATERIALS AND METHODS 500 
Bacterial strains, media and chemicals 501 
The bacterial strains, clinical isolates, plasmids and oligonucleotides used in this study are 502 
listed in Table S1, S2, S3 and S4, respectively. Bacterial strains were routinely grown at 37°C in 503 
Luria-Bertani Broth (LB) with aeration and, when necessary, antibiotics were added at the 504 
following concentrations: tetracycline (Tc), 200 μg/mL; carbenicillin (Cb), 150 μg/mL; 505 
gentamicin (Gm), 100 μg/mL; kanamycin (Km), 200 μg/mL. When necessary, isopropyl β-D-1-506 
thiogalactopyranoside (IPTG) was added at the concentrations indicated in the text. Muller-507 
Hinton Broth (MHB) and M9 minimal medium supplemented with 20 mM glucose as carbon 508 
source were used in the MIC assay (Clinical and Laboratory Standards Institute, CLSI) and in 509 
the biofilm assay, respectively. Synthetic HHQ and PQS stock solutions were prepared in 510 
MeOH. Clotrimazole, clofoctol and miconazole were purchased from Sigma-Aldrich and 511 
dissolved in DMSO. 512 
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Primary screening for the identification of pqs inhibitors 513 
P. aeruginosa PAO1 and the AQ-Rep biosensor strain (PAO1 ΔpqsA PpqsA::luxCDABE) 514 
were grown overnight at 37°C on LB agar plates. Bacteria were scraped from plate surfaces and 515 
diluted in LB to an optical density (OD) at 600 nm wavelength (OD600) of 0.1 and 0.03 for the 516 
biosensor and PAO1 strains, respectively [procedure modified from (57)]. Two-hundred μL 517 
aliquots of the coculture were grown at 37°C in 96-well microtiter plates in LB supplemented 518 
with each compound of the PHARMAKON library (20 µM and 200 μM). The OD600 and relative 519 
light units (RLU) were measured after 5 h incubation by using a Wallac 1420 Victor
3
V 520 
multilabel plate reader (PerkinElmer). Eight samples grown in the presence of DMSO (0.2% or 521 
2%) were used as controls in each microtiter plate. Reporter activity was determined as 522 
RLU/OD600 for each sample. Residual reported activity was determined in treated sample 523 
relative to the control samples grown in the presence of DMSO, considered as 100%. 524 
A similar approach was used to investigate the effect of the hits on the las and rhl QS 525 
systems. In this case, cocultures of the P. aeruginosa PAO1 wild type strain and of the PA14-R3 526 
(PA14 ΔlasI PrsaL::luxCDABE; 57) or the C4-Rep (PAO1 ∆rhlI PrhlA::luxCDABE; 24) 527 
biosensor strains were used, respectively. 528 
 529 
Quantification of AQs 530 
Levels of AQ signal molecules in treated-P. aeruginosa PAO1 culture supernatants were 531 
determined by using the reporter strain AQ-Rep, as previously described (102). Bacterial 532 
cultures were grown in 96-well microtiter plates at 37°C with shaking. Supernatants were 533 
collected after 16 h for the experiments shown in in Figs. 2B, 3A and S2, or after 24 h for 534 
experiments shown in Figs. 7B and S9, to allow optimal AQ production in slow-growing clinical 535 
isolates. Briefly, 10 μL of culture supernatant was added to 190 μL of LB inoculated with AQ-536 
Rep biosensor (final OD600 = 0.1) in 96-well microtiter plates. Microtiter plates were incubated 537 
at 37°C with gentle shaking, and the OD600 and RLU were measured after 5 h of incubation. A 538 
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calibration curve was generated by growing the AQ-Rep biosensor in the presence of increasing 539 
concentrations of synthetic HHQ or PQS; the resulting dose-response curve was used to calculate 540 
the concentration of the AQ signals in each culture supernatant. 541 
AQs produced by P. aeruginosa PAO1 were also quantified in by LC-MS/MS analysis, as 542 
previously described (103). Briefly, PAO1 was inoculated into 5 mL of LB in the absence or in 543 
the presence of 100 μM clofoctol. After 16 h incubation at 37°C with shaking, cell density of the 544 
culture was recorded and the supernatants were filter-sterilized. Supernatants were solvent 545 
extracted with ethyl acetate, dried under vacuum and re-dissolved in MeOH prior to quantitative 546 
analysis by LC-MS/MS. For each sample, a supernatant concentration of HHQ and PQS was 547 
calculated by comparing analytic peak areas with a matched calibration line. 548 
 549 
Pyocyanin production, swarming motility and biofilm formation assays 550 
Pyocyanin was extracted and quantified from P. aeruginosa PAO1 and ∆pqsR grown in LB 551 
supplemented with 100 µM clofoctol or with DMSO as a control, as previously described (104). 552 
Swarming motility assays were performed on swarming plates [0.8% (wt/vol) nutrient broth N.2, 553 
0.5% (wt/vol) glucose, 0.5% (wt/vol) bacteriological agar]. Plates were supplemented with or 554 
without clofoctol (100 µM). After 16 h of growth at 37°C, swarming motility was directly 555 
observed at the air-agar interface. 556 
For microscopic visualization of biofilms, P. aeruginosa PAO1 or ∆pqsR constitutively 557 
expressing GFP via the pMRP9-1 plasmid (60) were grown in an 8-well chamber slide, as 558 
previously described (105), with minor modifications. Briefly, bacterial cells were inoculated at 559 
an OD600 of 0.02 in 700 µL of M9 minimal medium supplemented with 20 mM glucose as 560 
carbon source, in the absence or in the presence of 100 µM clofoctol. Cultures were incubated at 561 
30°C for 24 h to allow the adhesion of the bacterial cells to the glass surface. To maintain 562 
bacterial viability, the medium was changed every 24 h. Biofilm formation was examined after 3 563 
days incubation by using the Leica TCS SP5 confocal microscope. 564 
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Western immunoblotting 565 
Crude protein extracts were collected from the P. aeruginosa PAO1 pqsA∆pqsH∆pqsR triple 566 
mutant strain carrying the pPqsR-6H plasmid grown in LB supplemented with 10 µM PQS and 567 
20 µM IPTG, in the absence or in the presence of 100 µM clotrimazole, clofoctol or miconazole. 568 
The P. aeruginosa PAO1 pqsA∆pqsH∆pqsR strain carrying the pME6032 empty vector was used 569 
as a control. The Bradford assay (106) was used to quantify and normalize total protein content 570 
in the samples. Western immunoblotting was performed by using a standard technique (107) 571 
with mouse anti-6His antibody (1:5,000; Sigma-Aldrich) and goat anti-mouse IgG HRP-572 
conjugate as secondary antibody (1:6,000; Bio-Rad Laboratories). Final development was 573 
performed with Amersham ECL chemiluminescent reagents (Amersham Biosciences). A C-574 
DiGit blot scanner (LI-COR Biosciences) was used for data acquisition. 575 
 576 
RNA extraction and Real Time RT-PCR analysis 577 
P. aeruginosa PAO1 and ∆pqsR were inoculated at an OD600 of 0.02 in 5 mL of LB in the 578 
absence or in the presence of 100 μM clotrimazole, clofoctol or miconazole. Cultures were 579 
grown at 37°C with vigorous shaking until they reached an OD600 of 2.0, and then 1 mL of cells 580 
was harvested by centrifugation and resuspended in 2 mL of RNAprotect Bacteria Reagent 581 
(Qiagen). Total RNA extraction was performed with the RNeasy Mini Columns Kit (Qiagen) 582 
according to the manufacturer’s instructions, including the on-column DNase I digestion step. In 583 
addition, eluted RNA was treated for 1 h at 37°C with DNase TURBO (0.2 U per µg of RNA; 584 
Ambion) and with SUPERase-In (0.4 U per µg of RNA; Ambion). DNase I was removed using 585 
the RNeasy Column Purification kit (Qiagen). Purified RNA was quantified using the NanoDrop 586 
2000 spectrophotometer (Thermo-Fisher Scientific). The absence of genomic DNA in the RNA 587 
samples was verified by PCR performed with primers FWPpqsL and RVPpqsL (Table S4). 588 
cDNA synthesis was performed with the iScript Reverse Transcription Supermix for RT-qPCR 589 
kit (Bio-Rad Laboratories) according to manufacturer’s instructions, and quantified with 590 
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 Green 591 
Supermix kit (Bio-Rad Laboratories), according of the manufacturer’s instructions, and the Rotor 592 
Gene 6000 thermocycler (Corbett Research). Primers employed in Real Time RT-PCR analysis 593 
were designed using the Primer-blast software (www.ncbi.nlm.nih.gov/tools/primer-blast) and 594 
are listed in Table S4. The reaction procedure involved incubation at 95°C for 1 min and 40 595 
cycles of amplification at 95°C for 10 s and 60°C for 45 s. Fluorescence was registered in the 596 
last 15 s of the 60°C step. 16S ribosomal RNA was chosen as an internal control (housekeeping 597 
gene) to normalize the Real Time RT-PCR data in each single run, and to calculate the relative 598 
fold change in gene expression by using the 2
-ΔΔCt
 method. The average data and standard 599 
deviations were calculated from three independent experiments. 600 
 601 
Galleria mellonella killing assay 602 
The G. mellonella killing assay was performed as previously described (63,65), with minor 603 
modifications. Briefly, G. mellonella caterpillars in the final instar larval stage (average weight, 604 
486 ± 67 mg) were infected with 10 μL of saline containing about 10 bacterial cells, in the 605 
absence or in the presence of 5 mM clofoctol. Although PAO1 cells were incubated in the 606 
presence of clofoctol for less than 5 min before injection, preliminary assays showed that 5 mM 607 
clofoctol treatment (for up to 24 h) does not significantly affect PAO1 cell or larval viability 608 
(data not shown). G. mellonella larvae were incubated at 37°C in petri dishes (ten larvae per 609 
dish) and monitored for 120 h. Larvae were considered dead when they did not respond to gentle 610 
prodding. At least 30 larvae per condition were used in four independent experiments. Survival 611 
curves for the G. mellonella killing assay were generated by the Kaplan-Meier method. 612 
 613 
Molecular docking simulations  614 
Molecular docking simulations were carried out using DockingApp (108), a user friendly 615 
interface for the docking program AutoDock Vina (109). In all simulations, the search space 616 
 25 
(docking grid) included the whole PqsR co-inducer binding domain (CBD) structure, in order to 617 
carry out “blind” predictions of the ‘hit’ compound binding sites. 618 
Simulations were carried out on the apo (PDB ID: 4JVC) and holo (PDB ID: 4JVD) forms of 619 
the protein (59), both by keeping all protein residues rigid and by allowing flexibility only of the 620 
residues previously reported to be involved in PqsR binding to the natural ligand NHQ (i.e. ILE 621 
149, ALA 168, VAL 170, ILE 186, LEU 189, LEU 207, LEU 208, PHE 221, ILE 236, TYR 258, 622 
ASP 264, THR 265) (52). 623 
 624 
Statistical analysis 625 
Statistical analysis was performed with the software GraphPad Prism 5, using one-way 626 
analysis of variance (ANOVA) followed by Tukey-Kramer multiple comparison tests. 627 
Differences having a p value < 0.05 were considered statistically significant. 628 
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FIGURE LEGENDS 963 
Figure 1. Validation of the screening system. 964 
(A) Schematic representation of the coculture-based reporter system. The P. aeruginosa PAO1 965 
strain (PAO1) produces AQ signal molecules which activate PpqsA::luxCDABE transcription, 966 
that results in light emission in the biosensor strain AQ-Rep. Drugs interfering with AQ 967 
biosynthesis or response are expected to reduce bioluminescence in the PAO1/AQ-Rep 968 
coculture, relative to the untreated samples. (B) Activity of the PAO1/AQ-Rep coculture system 969 
treated with indicated concentrations of the pqs inhibitors methyl anthranilate (white bars) or 970 
farnesol (grey bars). Bioluminescence of the untreated PAO1/AQ-Rep coculture normalized to 971 
cell density is considered as 100%. 972 
 973 
Figure 2. Clotrimazole, clofoctol and miconazole inhibit PpqsA activity and AQ production. 974 
Effect of clotrimazole (white bars), clofoctol (light-grey bars) and miconazole (dark-grey bars) 975 
on the PAO1/AQ-Rep coculture system. Bioluminescence of the untreated PAO1/AQ-Rep 976 
coculture normalized to cell density is considered as 100%. (B) Effect of clotrimazole (white 977 
bars), clofoctol (light-grey bars) and miconazole (dark-grey bars) on AQ production in PAO1. 978 
The level of AQs produced by untreated PAO1 is considered as 100%. For both (A) and (B), the 979 
average of at least three independent experiments is reported with SD. 980 
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 981 
Figure 3. Clotrimazole, clofoctol and miconazole inhibit AQ reception. 982 
(A) Production of AQs in P. aeruginosa PAO1 ∆pqsAH(pFD-pqsABCD) grown for 16 h in LB 983 
in the absence or in the presence of clotrimazole (white bars), clofoctol (light-grey bars) and 984 
miconazole (dark-grey bars). The AQ level measured in the untreated sample is considered as 985 
100%. (B) Activity of the AQ-Rep biosensor strain grown in LB supplemented with 10 µM 986 
synthetic PQS and clotrimazole (white bars), clofoctol (light-grey bars) or miconazole (dark-grey 987 
bars). Bioluminescence of the untreated AQ-Rep biosensor normalized to its cell density is 988 
considered as 100%. For both (A) and (B), the average of at least three independent experiments 989 
is reported with SD. 990 
 991 
Figure 4. Clotrimazole, clofoctol and miconazole inhibit PqsR functionality. 992 
(A) Real Time RT-PCR analysis showing the mRNA level of pqsR in PAO1 cultures treated 993 
with 100 µM of the indicated drugs relative to untreated PAO1 cultures. The PAO1 ∆pqsR strain 994 
was used as a negative control. The average of three independent experiments is reported with 995 
SD. ns, non-significant difference; ***, p < 0.001 (ANOVA). (B) Western immunoblotting 996 
performed with anti-6xHis antibody on crude protein extracts of PAO1 ∆pqsAHR(pPqsR-6H) 997 
grown in LB supplemented with 10 µM PQS and 20 µM IPTG, in the absence (untreated) or in 998 
the presence of the indicated drugs (100 µM). The PAO1 ∆pqsAHR strain carrying the empty 999 
vector pME6032 was used as a control. The data are representative of three independent 1000 
experiments. (C) Effect of 100 µM clotrimazole (white bars), clofoctol (light-grey bars) and 1001 
miconazole (dark-grey bars) on PpqsA::lux activity in the PAO1 ∆pqsA∆pqsH∆pqsR mutant 1002 
carrying the pPqsR-6H plasmid, grown in LB supplemented with 10 µM PQS and different 1003 
concentrations of IPTG as indicated in the graph. The average of three independent experiments 1004 
is reported with SD. 1005 
Figure 5. Putative complexes formed by clotrimazole, clofoctol and miconazole with the 1006 
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PqsR CBD. 1007 
Schematic representation of the complexes formed by clotrimazole (A), clofoctol (B) and 1008 
miconazole (C) with the PqsR co-inducer binding domain (CBD), obtained by molecular 1009 
docking simulations (see Materials and Methods for details). The three drugs are represented in 1010 
red, while the natural ligand NHQ is represented is green. 1011 
 1012 
Figure 6. Clofoctol inhibits the expression of pqs-controlled virulence traits. 1013 
(A) Concentrations of HHQ (white bars) and PQS (grey bars) measured by LC-MS/MS on 1014 
supernatants of PAO1 cultures grown for 16 h in LB in the absence or in the presence of 1015 
clofoctol at the indicated concentrations. The average of three independent experiments is 1016 
reported with SD. **, p = 0.0062; ***, p < 0.001 (ANOVA). (B) Effect of 100 µM clofoctol on 1017 
pyocyanin production, (C) swarming motility, and (D) biofilm formation in PAO1. The same 1018 
phenotypes were evaluated in the ∆pqsR mutant as a control. For pyocyanin production (B), the 1019 
average of three independent experiments is reported with SD and representative supernatants 1020 
are shown in the inset picture. ***, p < 0.001 (ANOVA). For swarming motility (C) and biofilm 1021 
formation (D), representative pictures of three independent experiments are shown. (E) Real 1022 
Time RT-PCR analysis showing mRNA level of the indicated genes in PAO1 treated with 100 1023 
µM clofoctol (white bars) and in ∆pqsR (grey bars) relative to untreated PAO1. The average of 1024 
three independent experiments is reported with SD. **, p = 0.0012; ***, p < 0.001 (ANOVA). 1025 
 1026 
Figure 7. Clofoctol displays an antivirulence effect in vivo and inhibits the pqs QS system in 1027 
P. aeruginosa CF clinical isolates. 1028 
(A) Kaplan-Meier plot showing the percentage survival of G. mellonella larvae inoculated with 1029 
P. aeruginosa PAO1 (blue line), with PAO1 and clofoctol at final concentration 100 µM (red 1030 
line), or with ∆pqsR (green line). The mean survival rate calculated from four independent 1031 
experiments performed on at least 30 larvae per condition is reported. **, p = 0.0033 for PAO1 1032 
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vs. PAO1 plus clofoctol; p = 0.0016 for PAO1 vs. ∆pqsR (ANOVA). (B) Dot plot showing the 1033 
inhibition of AQ production in P. aeruginosa CF isolates (filled symbols) and P. aeruginosa 1034 
PAO1 (open square) treated with 100 µM clofoctol, relative to the untreated samples considered 1035 
as 100%. Black lines represent the median values: all, 31.4%; first isolate, 25.2%; early chronic, 1036 
31.1%; middle chronic, 32.1%; late chronic, 57.8%. AQ production in treated PAO1 cultures 1037 
was 34.3% relative to untreated PAO1. Differences between the median values are not 1038 
statistically significant. Mean results of three independent experiments are reported.  1039 
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Table 1. Anti-pqs compounds identified by screening the PHARMAKON library of FDA-1040 
approved drugs. 1041 
















The IC50 values (µM) were determined by using the PAO1/AQ-Rep coculture system.
 
1043 
b ∆G values (kcal/mol) for drugs binding to the PqsR CBD apo form (PDB ID: 4JVC) (59) 1044 
predicted by molecular docking simulations. 1045 







